Lipid nanoparticles for drug delivery to the brain: In vivo veritas

Journal of Biomedical Nanotechnology

Volumn 5, Issue 4, 2009, Pages 344-350

  Blasi, Paolo ^a   Schoubben, Aurélie ^a   Giovagnoli, Stefano ^a   Rossi, Carlo ^a   Ricci, Maurizio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Blood brain barrier (BBB); Brain drug delivery; Colloids; Lipid colloidal dispersions; Neurovascular unit (NVU); Solid lipid nanoparticles (SLN)

Indexed keywords

BLOOD-BRAIN BARRIER; BLOOD-BRAIN BARRIER (BBB); COLLOIDAL DISPERSION; IN-VIVO; LIPID NANOPARTICLES; POLYMER CARRIER; SOLID LIPID NANOPARTICLES; VERITAS;

BLOOD; COLLOID CHEMISTRY; DISPERSIONS; DRUG DELIVERY;

NANOPARTICLES;

CAMPTOTHECIN; CLOZAPINE; CYANOACRYLATE DERIVATIVE; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; FLOXURIDINE; FLOXURIDINE 3',5' DIOCTANOATE; IDARUBICIN; PACLITAXEL; SOLID LIPID NANOPARTICLE; TOBRAMYCIN;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; EVIDENCE BASED MEDICINE; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DRUG CARRIERS; HUMANS; LIPIDS; NANOMEDICINE;

EID: 70450160818     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1043     Document Type: Review

References (85)

1. Y. Su and P. J. Sinko, Drug delivery across the blood-brain barrier why is it difficult? How to measure and improve it?. Expert Opin. Drug Deliv. 3, 419 (2006).
2. W. M. Pardridge, Blood-brain barrier drug targeting: The future of brain drug development. Mol. Interv. 3, 90 (2003).
3. P. Ballabh, A. Braun, and M. Nedergaard, The blood-brain barrier An overview structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1 (2004).
4. E. M. Cornford and S. Hyman, Blood-brain barrier permeability to small and large molecules. Adv. Drug Deliv. Rev. 36, 145 (1999).
5. N. J. Abbott, Evidence for bulk flow of brain interstitial fluid: Significance for physiology and pathology. Neumchem. Int. 45, 545 (2004).
6. J. Siepmann, F. Siepmann, and A. T. Florence, Local controller drug delivery to the brain: Mathematical modeling of the underlying mass transport mechanisms. Int. J. Pharm. 314, 101 (2006).
7. World Health Organization, The Global Burden of Disease Project, http://www.who.int (last accessed 1 April 2009).
8. Intercontinental Market Services (IMS), World Review (2004). http://imshealth.com (last accessed 1 April 2009)
9. R. N. Lawrence, Sir richard sykes contemplates the future of the pharma industry. Drug Discov. Today 7, 645 (2002).
10. W. M. Pardridge, ed., Brain Drug Targeting: The Future of Brain Drug Development, Cambridge University Press, Cambridge, U.K. (2001).
11. M. Ricci, P. Blasi, S. Giovagnoli, and C. Rossi, Delivering drugs to the central nervous system: A medicinal chemistry or a pharmaceutical technology issue? Curr. Med. Chem. 13, 1757 (2006).
12. W. M. Pardridge, Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today 7, 5 (2002).
13. R. N. Lawrence, William Pardridge discusses the lack of BBB research. Drug Discov. Today 7, 223 (2002).
14. D. E. Clark, In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8, 927 (2003).
15. A. M. Aronov, Predictive in silico modeling for hERG channel blockers. Drug Discov. Today: Biosilico 10, 149 (2005).
16. P. J. Gaillard, C. C. Visser, A. G. de Boer, Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv. 2, 299 (2005).
17. N. Butowski and S. M. Chang, Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control 12, 116 (2005).
18. U. Lungwitz, M. Breunig, T. Blunk, and A. Gopferich, Polyethyleniminebased non-viral gene delivery systems. Eur. J. Pharm. Biopharm. 60, 247 (2005).
19. S. B. Tiwari and M. M. Amiji, A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 3, 219 (2006).
20. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur, Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298, 274 (2005).
21. D. Klose, M. Laprais, V. Leroux, F. Siepmann, B. Deprez, R. Bordet, and J. Siepmann, Fenofibrate-loaded PLGA microparticles: Effects on ischemic stroke. Eur. J. Pharm. Sci. 37, 43 (2009).
22. P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, and C. Rossi, Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59, 454 (2007).
23. I. P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar, Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97 (2008).
24. R. H. Müller, K. Mäder, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161 (2000).
25. S. A. Wissing, O. Kayser, and R. H. Müller, Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257 (2004).
26. R. H. Müller and S. Schmidt, Pathfinder technology for the delivery of drugs to the brain. New Drugs 2, 38 (2002).
27. R. H. Müller and C. M. Keck, Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 4, 471 (2004).
28. B. Siekmann and K. Westesen, Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1, 123 (1992).
29. R. H. Müller and J. S. Lucks, Medication vehicles made of solid lipid particles (solid lipid nanospheres - SLN) EP 0605497 (1996).
30. M. R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution, U. S. Patent 5,250,236 (1993).
31. R. H. Müller, Lipid nanoparticles: Recent advances. Adv. Drug Deliv. Rev. 59, 375 (2007).
32. R. H. Müller, M. Radtke, and S. A. Wissing, Encyclopedia of Nanoscience and Nanotechnology, edited by H. S. Nalwa, American Scientific Publishers, Los Angeles (2004), Vol.10, pp. 43-56.
33. C. Puglia, P. Blasi, L. Rizza, A. Schoubben, F. Bonina, C. Rossi, and M. Ricci, Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int. J. Pharm. 357, 295 (2008).
34. M. A. Casadei, F. Cerreto, S. Cesa, M. Giannuzzo, M. Feeney, C. Marianecci, and P. Paolicelli, Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations. Int. J. Pharm. 325, 140 (2006).
35. R. Cavalli, M. R. Gasco, P. Chetoni, S. Burgalassi, and M. F. Saettone, Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238, 241 (2002).
36. S. Doktorovova and E. B. Souto, Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin. Drug Deliv. 6, 165 (2009).
37. S. C. Yang, J. B. Zhu, Y. Lu, B. W. Liang, and C. Z. Yang, Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16, 751 (1999).
38. G. P. Zara, R. Cavalli, A. Fundarò, A. Bargoni, O. Caputo, and M. R. Gasco, Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 40, 281 (1999).
39. T. Minagawa, K. Sakanaka, S. I. Inaba, Y. Sai, I. Tamai, T. Suwa, and A. Suji, Blood-brain-barrier transport of lipid microspheres containing linprost, a prostaglandin 12 analogue. J. Pharm. Pharmacol. 48, 1016 (1996).
40. V. Podio, G. P. Zara, M. Carazzone, R. Cavalli, and M. R. Gasco, Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J. Pharm. Pharmacol. 52, 1057 (2000).
41. A. Fundarò, R. Cavalli, A. Bargoni, D. Vighetto, G. P. Zara, and M. R. Gasco, Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 42, 337 (2000).
42. S. C. Yang, L. F. Lu, Y. Cai, J. B. Zhu, B. W. Liang, and C. Z. Yang, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59, 299 (1999).
43. J. M. Koziara, P. R. Lockman, D. D. Allen, and R. J. Mumper, In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20, 1772 (2003).
44. J. M. Koziara, P. R. Lockman, D. D. Allen, and R. J. Mumper, Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 99, 259 (2004).
45. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. R. Murthy, Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 6, Article 23 (2004).
46. K. Manjunath and V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107, 215 (2005).
47. L. H. Reddy, R. K. Sharma, K. Chuttani, A. K. Mishra, and R. S. R. Murthy, Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 105, 185 (2005).
48. A. Bargoni, R. Cavalli, G. P. Zara, A. Fundarò, O. Caputo, and M. R. Gasco, Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - tissue distribution. Pharmacol. Res. 43, 497 (2001).
49. G. P. Zara, A. Bargoni, R. Cavalli, A. Fundarò, D. Vighetto, and M. R. Gasco, Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91 1324 (2002).
50. J. X. Wang, X. Sun, and Z. R. Zhang, Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 54, 285 (2002).
51. R. H. Müller and C. M. Keck, Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113, 151 (2004).
52. C. Olbrich, A. Gessner, O. Kayser, and R. H. Müller, Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target. 10, 387 (2002).
53. A. Gessner, C. Olbrich, W. Schröder, O. Kayser, and R. H. Müller, The role of plasma proteins in brain targeting: Species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214, 87 (2001).
54. J. Kreuter, V. E. Petrov, D. A. Kharkevich, R. N. Alyautdin, Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant coated nanoparticles. J. Control. Release 49, 81 (1997).
55. B. Petri, A. Bootz, A. Khalansky, T. Hekmatara, R. Müller, R. Uhl, J. Kreuter, and S. Gelperina, Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate nanoparticles: Revisiting the role of surfactants. J. Control. Release 117, 51 (2007).
56. E. Peira, P. Marzola, V. Podio, S. Aime, A. Sbarbati, and M. R. Gasco, In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J. Drug Target. 11, 19 (2003).
57. J. Kreuter, K. Michaelis, S. Dreis, K. Langer, eds. The role of apolipoprotein on brain uptake of nanoparticles-bound drugs. Proceedings of the 15th International Symposium on Microencapsulation, September 18-21, Parma, Italy (2005).
58. K. Michaelis, M. M. Hoffmann, S. Dreis, E. Herbert, R. N. Alyautdin, M. Michaelis, J. Kreuter, and K. Langer, Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317, 1246 (2006).
59. R. H. Müller, S. Heinemann, Bioadhesion - Possibilities and Future Trends, edited by R. Gurny and H. E. Junginger, Wissenschaftliche Verlagsgesellschaft, Stuttgart (1989), pp. 202-214.
60. T. M. Göppert and R. H. Müller, Plasma protein adsorption of Tween® 80- and poloxamer 188-stabilized solid lipid nanoparticles. J. Drug Target. 11, 225 (2003).
61. T. M. Göppert and R. H. Müller, Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int. J. Pharm. 302, 172 (2005).
62. H. Weyhers, M. Lück, W. Mehnert, E. B. Souto, and R. H. Müller, Surface modified solid lipid nanoparticles (SLN) analysis of plasma protein adsorption patterns by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). Int. J. Mol. Med. Adv. Sci. 1, 196 (2005).
63. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin, Apolipoprotein-mediated transport of nanoparticlebound drugs across the blood-brain barrier. J. Drug Target. 10, 317 (2002).
64. N. S. Chung and K. M. Wasan, Potential role of the low density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56, 1315 (2004).
65. B. Dehouck, L. Fenart, M. P. Dehouck, A. Pierce, G. Torpier, and R. Cecchelli, A new function for the LDL receptor transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877 (1997).
66. M. W. Smith and M. Gumbleton, Endocytosis at the blood-brain barrier From basic understanding to drug delivery strategies. J. Drug Target. 14, 191 (2006).
67. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Büchel, H. von Briesen, and J. Kreuter, Albumin nanoparticles targeted with ApoE enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137, 78 (2009).
68. R. N. Alyautdin, D. Gothier, V. Petrov, D. Kharkevich, and J. Kreuter, Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41, 44 (1995).
69. J. Kreuter, Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 4, 484 (2004).
70. J. Kreuter, T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, and K. Langer, Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release 118, 54 (2007).
71. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S. E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D. J. Begley, Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20, 409 (2003).
72. J. Kreuter, Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser. 1277, 85 (2005).
73. J. C. Olivier, L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16, 1836 (1999).
74. P. R. Lockman, J. Koziara, K. E. Roder, J. Paulson, T. J. Abbruscato, R. J. Mumper, and D. D. Allen, In vivo and in vitro assessment of baseline bloodbrain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20, 705 (2003).
75. A. V. Kabanov, E. V. Batrakova, and D. W. Miller, Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev. 55, 151 (2003).
76. P. R. Lockman, J. M. Koziara, R. J. Mumper, and D. D. Allen, Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12, 635 (2004).
77. H. Weyhers, W. Mehnert, H. Hahn, R. H. Müller, (eds.), Solid lipid nanoparticles-determination of in vivo toxicity, Proceedings of the first World Meeting APGI/APV, May 9-11, Budapest, Hungary (1995).
78. S. Koennings, A. Sapin, T. Blunk, P. Menei, and A. Goepferich, Towards controlled release of BDNF-Manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J. Contol. Release 119, 163 (2007).
79. F. Kreye, F. Siepmann, and J. Siepmann, Lipid implants as drug delivery systems. Expert Opin. Drug Deliv. 5, 291 (2008).
80. C. Vauthier, C. Dubernet, E. Fattal, H. Pinto-Alphandary, and P. Couvreur, Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55, 519 (2003).
81. R. Fernandez-Urrusuno, E. Fattal, D. Porquet, J. Feger, and P. Couvreur, Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol. Appl. Pharmacol. 130, 272 (1995).
82. R. Femandez-Urrusuno, E. Fattal, J. Feger, P. Couvreur, and P. Thérond, Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials 18, 511 (1997).
83. R. H. Müller, M. Radtke, and S. A. Wissing, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54, S131 (2002).
84. L. Luillerat-Jeanneret, The targeted delivery of cancer drugs across the blood-brain barrier chemical modifications of drugs or drug-nanoparticles? Drug Discov. Today 13, 1099 (2008).
85. G. Tosi, L. Costantino, B. Ruozi, F. Forni, and M. A. Vandelli, Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin. Drug Deliv. 5, 155 (2008).